ASC30 vs Berobenatide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

ASC30

Developed by Ascletis Pharma

Phase 3 in Obesitysmall molecule
Partial signal

NCT07002905 · Phase 2 · completed

The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: July 2028 · NCT07743463 (registry estimate)

Reported efficacy

Percent change in body weight from Baseline up to Week 13 (Baseline and Week 13): Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo (met)

Result source: NCT07002905

Berobenatide

Developed by Pfizer

Phase 3 in Obesitypeptide
Partial signal

NCT06712836 · Phase 2 · completed

The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2027 · NCT07508241 (registry estimate)

Reported efficacy

Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197)): Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). (met)

Result source: NCT06712836

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointASC30Berobenatide
Body weight, % change—Trial running · NCT07743463—Trial running · NCT07311850
Weight loss of 5% or more—Trial running · NCT07743463—Trial running · NCT07311850
Weight loss of 10% or more—Trial running · NCT07743463—Trial running · NCT07311850
Waist circumference, change (cm)—Trial running · NCT07743463—Trial running · NCT07311850

Body weight, % change

ASC30
—Trial running · NCT07743463
Berobenatide
—Trial running · NCT07311850

Weight loss of 5% or more

ASC30
—Trial running · NCT07743463
Berobenatide
—Trial running · NCT07311850

Weight loss of 10% or more

ASC30
—Trial running · NCT07743463
Berobenatide
—Trial running · NCT07311850

Waist circumference, change (cm)

ASC30
—Trial running · NCT07743463
Berobenatide
—Trial running · NCT07311850
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Berobenatide
Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). NCT06712836 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ASC30

Weight 7.7% @ 13wk60mg ASC30
percent change · % of baseline
No placebo or comparator arm
NCT07002905 · Phase 2 · sponsor-reported, not registry data
show 2 more results
7% @ 13wk40mg ASC30
NCT07002905 · Phase 2 · sponsor-reported, not registry data
5.4% @ 13wk20mg ASC30
NCT07002905 · Phase 2 · sponsor-reported, not registry data

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

ASC30

Developed by Ascletis Pharma

Phase 3 in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT07743450 (registry estimate)

No aligned efficacy figure on record for this race.

Berobenatide

Developed by Pfizer

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06897202 · Phase 2 · completed

The trial randomly assigned 133 participants to MET097 or placebo and was double-blinded, with percent change in body weight as the primary clinical endpoint. However, because no primary efficacy results are available, it is not possible to determine whether the endpoint was met.

Figures from conference coverage of the ADA 2026 presentation; weight change is from baseline, not placebo-adjusted, and no significance testing was reported for the weight endpoint. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: October 2027 · NCT07400653 (registry estimate)

Reported efficacy

Percent change from baseline in body weight at Week 28 (Day 197) (Baseline (Week 0) through Week 28 (Day 197)): Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose

Result source: NCT06897202

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointASC30Berobenatide
HbA1c, change—Trial running · NCT07743450—Trial running · NCT07400653
Body weight, change (kg)—Trial running · NCT07743450—Trial running · NCT07400653
HbA1c below 7%—Trial running · NCT07743450—Trial running · NCT07400653
Fasting plasma glucose, change—Trial running · NCT07743450—Trial running · NCT07400653
3-point MACE (% with event)—Trial running · NCT07743450—Trial running · NCT07400653

HbA1c, change

ASC30
—Trial running · NCT07743450
Berobenatide
—Trial running · NCT07400653

Body weight, change (kg)

ASC30
—Trial running · NCT07743450
Berobenatide
—Trial running · NCT07400653

HbA1c below 7%

ASC30
—Trial running · NCT07743450
Berobenatide
—Trial running · NCT07400653

Fasting plasma glucose, change

ASC30
—Trial running · NCT07743450
Berobenatide
—Trial running · NCT07400653

3-point MACE (% with event)

ASC30
—Trial running · NCT07743450
Berobenatide
—Trial running · NCT07400653
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ASC30: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Berobenatide
Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose NCT06897202 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · Berobenatide's landscape